Browse the corpus

Allergic conjunctivitis: Ophthalmic: Children ≥2 years: Refer to adult dosing. Dosing: Geriatric Refer to adult dosing. Dosing: Renal Impairment No dosage adjustment provided in the manufacturer’s labeling. Dosing: Hepatic Impairment No dosage adjustment provided in the manufacturer’s labeling. Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Solution, ophthalmic [drops]: Lastacaft™: 0.25% (3 mL) [contains benzalkonium chloride] Generic Equivalent Available: U.S. No Administration For topical ophthalmic use only. Contact lenses should be removed prior to application, and may be reinserted 10 minutes after administration. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip with affected eye(s). Use Prevention of itching associated with allergic conjunctivitis Adverse Reactions Significant 1% to 10%: Central nervous system: Headache (<3%) Ocular: Ocular reactions (<4%; includes burning, pruritus, irritation, redness, stinging) Respiratory: Nasopharyngitis (<3%) Miscellaneous: Influenza (<3%) Contraindications There are no contraindications listed within the manufacturer’s labeling. Warnings/Precautions

Special populations: • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses prior to administration and wait 10 minutes before reinserting.

Other warnings/precautions: • Appropriate use: For topical ophthalmic use only. Not for the treatment of contact lens irritation; do not wear contact lens if eye is red. To avoid contamination, do not touch dropper tip to any surface. Metabolism/Transport Effects None known. Drug Interactions (For additional information: Launch Lexi-Interact™ Drug Interactions Program ) There are no known significant interactions. Pregnancy Risk Factor B ( show table ) Pregnancy Implications There are no well-controlled studies in pregnant women. Animal studies showed no evidence of teratogenicity or harm to the fetus. Lactation Excretion in breast milk unknown/use caution Pricing: U.S. (Medi-Span®)

Solution (Lastacaft Ophthalmic) 0.25% (3 mL): $138.31 Mechanism of Action Direct H 1 -receptor antagonist and inhibitor of histamine release from mast cells Pharmacodynamics/Kinetics Absorption: Minimal systemic absorption Protein binding: ~40%; Carboxylic acid (metabolite): ~60% Metabolism: Non-CYP450 cytosolic enzymes to the active metabolite carboxylic acid Half-life elimination: Carboxylic acid: ~2 hours Use of UpToDate is subject to the Subscription and License Agreement . Topic 15587 Version 26.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]